245 First Street, Riverview II
18th Floor
Cambridge, MA 02142
United States
857 327 8778
https://www.cyclerion.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 1
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Regina Graul Ph.D. | President | 372k | N/D | N/D |
Ms. Rhonda M. Chicko | Chief Financial Officer | N/D | N/D | 1966 |
Dr. Todd Milne Ph.D. | Senior Vice President of External Innovation | N/D | N/D | N/D |
Ms. Jessica Rennekamp | Associate Director of Corporate Communications | N/D | N/D | N/D |
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
La calificación ISS Governance QuickScore de Cyclerion Therapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.